Middle Eastern cancer collaboration agreement

24 November 2022

The European Organization for Research and Treatment of Cancer (EORTC) has entered into a collaboration aimed at bringing treatment and research in the oncology sector to patients in the Middle East.

Today, the Brussels, Belgium-based EORTC and the King Hussein Cancer Center (KHCC) in Amman, Jordan, announce the signing of an agreement to develop, conduct, and promote translational and clinical cancer research in the Middle East region. The KHCC will act as the Middle East Co-ordinating Office (MECO) and will provide support to EORTC for its activities.

This is the first EORTC collaboration in the region and will form an important part of its effort to develop cancer research in middle-income countries where many patients have not yet had the opportunity to take part in clinical trials

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK